CYNATA THERAPEUTICS LTD

CYP | Australian Stock Exchange Ltd

Business Summary

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.

Country of Incorporation

Australia

Incorporation Date

2003-03-12

Business Sector

Pharmaceuticals & Medical Research

Company Address

Level 3, 100 Cubitt Street,, Cremorne

Get access to the below data and more business development tools by signing up for the MENA Company Data product.

- Ownership details

- Corporate structure

- Business classification

- Officers & Directors contact details

- Full company contact details

Find out more

Multiply your reach by contributing your content to LSEG

LSEG contributed content reaches tens of thousands of buy and sell side professionals around the world through an integrated suite of market intelligence and transaction platforms.

Find out more